NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
67877-0537-14 | 67877-0537 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 28, 2017 | In Use | |
47335-0890-21 | 47335-0890 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
62559-0924-51 | 62559-0924 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 16, 2020 | Feb 28, 2023 | No Longer Used |
62559-0922-14 | 62559-0922 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 16, 2020 | Feb 28, 2023 | No Longer Used |
40051-0609-52 | 40051-0609 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
59923-0711-05 | 59923-0711 | temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan 25, 2019 | In Use | |
67877-0538-07 | 67877-0538 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 28, 2017 | In Use | |
67877-0540-07 | 67877-0540 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 28, 2017 | In Use | |
00085-1430-03 | 00085-1430 | Temozolomide | Temodar | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | In Use | |
43975-0254-05 | 43975-0254 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jul 13, 2016 | In Use | |
00781-2693-44 | 00781-2693 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | In Use | |
23155-0774-72 | 23155-0774 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jun 15, 2022 | Jun 15, 2022 | No Longer Used |
47335-0892-21 | 47335-0892 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
00085-1381-01 | 00085-1381 | Temozolomide | Temodar | 2.5 mg/mL | Chemotherapy | Alkylating Agent | Tetrazine | Intravenous | Feb 27, 2009 | In Use | |
51862-0084-14 | 51862-0084 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 10, 2016 | Mar 31, 2019 | In Use |
40051-0607-11 | 40051-0607 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
00093-7600-41 | 00093-7600 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | Jan 31, 2019 | In Use |
00074-1055-01 | 00074-1055 | Telisotuzumab Vedotin | EMRELIS | 100.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | c-MET | Intravenous | May 14, 2025 | In Use | |
00074-1044-01 | 00074-1044 | Telisotuzumab Vedotin | EMRELIS | 20.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | c-MET | Intravenous | May 14, 2025 | In Use | |
57894-0450-01 | 57894-0450 | Teclistamab | TECVAYLI | 90.0 mg/mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Oct 25, 2022 | In Use | |
57894-0449-01 | 57894-0449 | Teclistamab | TECVAYLI | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Oct 25, 2022 | In Use | |
80446-0401-01 | 80446-0401 | TEBENTAFUSP | KIMMTRAK | 100.0 ug/.5mL | Immunotherapy | T Cell Receptor (TCR) | HLA-A*02:01 | Intravenous | Jan 26, 2022 | In Use | |
63459-0910-01 | 63459-0910 | tbo-filgrastim | Granix | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 11, 2013 | In Use | |
63459-0912-17 | 63459-0912 | tbo-filgrastim | Granix | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Mar 2, 2015 | In Use | |
63459-0912-18 | 63459-0912 | tbo-filgrastim | Granix | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Jan 7, 2015 | In Use |
Found 11748 results — Export these results